Press Releases

GSK enters into a multi-year data licence agreement with Ochre Bio to further investigate the drivers of liver disease

Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence…

Merck Invests € 62 Million in New Quality Control Facility in Darmstadt, Germany

Merck, a leading science and technology company, announces an investment of € 62 million at its Darmstadt headquarters in a…

Syntis Bio launches to revolutionize oral therapy for obesity, diabetes and rare diseases by unlocking the full therapeutic potential of the small intestine

Syntis Bio, Inc. (Syntis) today announced its launch as a clinical-stage biopharmaceutical company with a mission to develop oral therapies…

Entos Pharmaceuticals receives approval from Health Canada to begin clinical trial for Covid-19 vaccine booster

Entos Pharmaceuticals, a clinical-stage biotechnology company developing genetic medicines with its proprietary Fusogenix PLV nucleic acid delivery platform, and its…

Moderna files FDA application for the JN.1 targeting Covid-19 vaccine

Moderna today announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) for review of…

HUTCHMED initiates Phase 1 trial of Menin Inhibitor HMPL-506 in patients with hematological malignancies in China

HUTCHMED today announces that it has initiated Phase I clinical trial of its menin inhibitor HMPL-506 in patients with hematological…

Nestlé Health Science agrees to acquire global rights to VOWST, product it launched in June 2023

Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health…

EnGeneIC and Singapore Institute of Advanced Medicine forge strategic partnership to revolutionise cancer treatment in Asia

EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has today announced strategic…

Acquisition of Fusion completed

AstraZeneca today announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates…

Johnson & Johnson submits supplemental new drug application to US FDA seeking expanded pediatric indication for HIV-1 therapy Prezcobix

Johnson & Johnson today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug…